Behavioral Digital Biomarkers Market Size and Growth
The global behavioral digital biomarkers market size was USD xx billion in 2023, calculated at USD xx billion in 2024 and is expected to reach around USD xx billion by 2033, expanding at a CAGR of xx% from 2024 to 2033.
Behavioral data about clinical psychiatry can be collected and analyzed, particularly with the help of electronic devices such as smartphones and wearable & implanted devices. Disease symptoms passively gathered from such devices, known as "digital health technologies," are referred to as behavioral digital biomarkers. For example, changes in speech and gait, slowed movement, and loss of automatic movements can be digitally measured to predict the presence of nervous system disorders, such as Parkinson's disease. Behavioral digital biomarkers in healthcare are still nascent but have been gaining popularity and momentum post-COVID-19 pandemic. Many market players are offering this technology, leading to a rise in their adoption. For example, Altoida is developing digital neurological disease biomarkers using machine learning and augmented reality. This technology platform allows an accurate evaluation of an individual’s functional and cognitive impairment, potential progression to Alzheimer’s disease, and symptomatic deficits due to amyloid pathology. Thus, the availability of such technologies in the market propels the market growth.
The growth of the behavioral digital biomarkers market is attributed to the rapid technological advancements in healthcare technology, the growing popularity of remote technologies and recent innovations, demand for remote patient monitoring services, and increasing healthcare expenditure. Furthermore, favorable initiatives started by the government and private organizations boost market growth. For instance, the National Alzheimer's Coordinating Center (NACC) and Gates Ventures organized the Alzheimer's Disease and Related Dementias (AD/ADRD) Digital Pilot Program to leverage digital tools to advance AD/ADRD research and discovery in 2023. The selection committee will choose one to three pilot projects. Funding of USD 0.25 to 1 million will be provided for these pilot projects that leverage technology to enable richer and more objective data collection with less burden for participants and ADRCs, advancing the development and validation of digital biomarkers for Alzheimer's. Furthermore, growing research activities and new product launch fuels the market growth. For instance, in January 2021, Biogen Inc. collaborated with Apple and conducted a new virtual research study to investigate the role of the iPhone and Apple Watch in monitoring cognitive health and screening for cognitive health decline, including mild cognitive issues. The study aims to determine digital biomarkers to aid in monitoring cognitive health and performance, including potentially identifying mild cognitive impairment, an early indicator of certain forms of dementia such as Alzheimer’s.
The behavioral digital biomarkers market has been classified into three segments, namely, type, clinical practice, and end use. The sharp rise in the usage of smartwatches, smartphones, and wearable digital technological devices such as fitness trackers and medical bracelets, as well as the continuous growth in yearly smartwatch sales, is contributing to the market's growth. Moreover, novel technology allows real-time monitoring of complicated diseases by detecting biomarkers such as speech, breathing, heat, brain health, and eye movements. For example, NEUROKEYS is a software platform that measures brain health via the energy levels of a person typing on a smartphone.
The emergence of entrepreneurial startups and the entry of niche market players offering specific solutions are boosting market growth. For example, Koneksa Health develops, tests, and validates digital biomarkers for neuroscience, Parkinson's disease, oncology, respiratory, and other therapeutic areas. Some other renowned market participants are Koneksa; Biogen Inc.; Amgen Inc.; Biogen Inc.; Empatica Inc.; Vivo Sense; and IXICO plc.
Behavioral Digital Biomarkers Market Top Key Companies:
Koneksa
Biogen Inc.
Amgen Inc.
Biogen Inc.
Empatica Inc.
Vivo Sense
IXICO plc
Huma
Sonde Health, Inc.
Clario
Behavioral Digital Biomarkers Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Behavioral Digital Biomarkers market.
By Type
Wearable
Mobile based Applications
Sensors
Others
By Clinical Practice
Diagnostic Psychiatric Digital Biomarkers
Monitoring Psychiatric Digital Biomarkers
Predictive and Prognostic Psychiatric Digital Biomarkers
Other's (Safety, Pharmacodynamics/ Response, Susceptibility)
By End Use
Healthcare companies
Healthcare Providers
Payers
Others (Patient, caregivers)
By Region
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa (MEA)
- Chapter 1. Introduction
- 1.1. Research Objective
- 1.2. Scope of the Study
- 1.3. Definition
- Chapter 2. Research Methodology (Premium Insights)
- 2.1. Research Approach
- 2.2. Data Sources
- 2.3. Assumptions & Limitations
- Chapter 3. Executive Summary
- 3.1. Market Snapshot
- Chapter 4. Market Variables and Scope
- 4.1. Introduction
- 4.2. Market Classification and Scope
- 4.3. Industry Value Chain Analysis
- 4.3.1. Raw Material Procurement Analysis
- 4.3.2. Sales and Distribution Channel Analysis
- 4.3.3. Downstream Buyer Analysis
- Chapter 5. COVID 19 Impact on Behavioral Digital Biomarkers Market
- 5.1. COVID-19 Landscape: Behavioral Digital Biomarkers Industry Impact
- 5.2. COVID 19 - Impact Assessment for the Industry
- 5.3. COVID 19 Impact: Global Major Government Policy
- 5.4. Market Trends and Opportunities in the COVID-19 Landscape
- Chapter 6. Market Dynamics Analysis and Trends
- 6.1. Market Dynamics
- 6.1.1. Market Drivers
- 6.1.2. Market Restraints
- 6.1.3. Market Opportunities
- 6.2. Porter’s Five Forces Analysis
- 6.2.1. Bargaining power of suppliers
- 6.2.2. Bargaining power of buyers
- 6.2.3. Threat of substitute
- 6.2.4. Threat of new entrants
- 6.2.5. Degree of competition
- Chapter 7. Competitive Landscape
- 7.1.1. Company Market Share/Positioning Analysis
- 7.1.2. Key Strategies Adopted by Players
- 7.1.3. Vendor Landscape
- 7.1.3.1. List of Suppliers
- 7.1.3.2. List of Buyers
- Chapter 8. Global Behavioral Digital Biomarkers Market, By Type
- 8.1. Behavioral Digital Biomarkers Market, by January, 2023-2032
- 8.1.1 Wearable
- 8.1.1.1. Market Revenue and Forecast (2020-2032)
- 8.1.2. Mobile based Applications
- 8.1.2.1. Market Revenue and Forecast (2020-2032)
- 8.1.3. Sensors
- 8.1.3.1. Market Revenue and Forecast (2020-2032)
- 8.1.4. Others
- 8.1.4.1. Market Revenue and Forecast (2020-2032)
- Chapter 9. Global Behavioral Digital Biomarkers Market, By Clinical Practice
- 9.1. Behavioral Digital Biomarkers Market, by February, 2023-2032
- 9.1.1. Diagnostic Psychiatric Digital Biomarkers
- 9.1.1.1. Market Revenue and Forecast (2020-2032)
- 9.1.2. Monitoring Psychiatric Digital Biomarkers
- 9.1.2.1. Market Revenue and Forecast (2020-2032)
- 9.1.3. Predictive and Prognostic Psychiatric Digital Biomarkers
- 9.1.3.1. Market Revenue and Forecast (2020-2032)
- 9.1.4. Other's (Safety, Pharmacodynamics/ Response, Susceptibility)
- 9.1.4.1. Market Revenue and Forecast (2020-2032)
- Chapter 10. Global Behavioral Digital Biomarkers Market, By End Use
- 10.1. Behavioral Digital Biomarkers Market, by March, 2023-2032
- 10.1.1. Healthcare companies
- 10.1.1.1. Market Revenue and Forecast (2020-2032)
- 10.1.2. Healthcare Providers
- 10.1.2.1. Market Revenue and Forecast (2020-2032)
- 10.1.3. Payers
- 10.1.3.1. Market Revenue and Forecast (2020-2032)
- 10.1.4. Others (Patient, caregivers)
- 10.1.4.1. Market Revenue and Forecast (2020-2032)
- Chapter 11. Global Behavioral Digital Biomarkers Market, Regional Estimates and Trend Forecast
- 11.1. North America
- 11.1.1. Market Revenue and Forecast, by January (2020-2032)
- 11.1.2. Market Revenue and Forecast, by February (2020-2032)
- 11.1.3. Market Revenue and Forecast, by March (2020-2032)
- 11.1.4. U.S.
- 11.1.4.1. Market Revenue and Forecast, by January (2020-2032)
- 11.1.4.2. Market Revenue and Forecast, by February (2020-2032)
- 11.1.4.3. Market Revenue and Forecast, by March (2020-2032)
- 11.1.5. Rest of North America
- 11.1.5.1. Market Revenue and Forecast, by January (2020-2032)
- 11.1.5.2. Market Revenue and Forecast, by February (2020-2032)
- 11.1.5.3. Market Revenue and Forecast, by March (2020-2032)
- 11.2. Europe
- 11.2.1. Market Revenue and Forecast, by January (2020-2032)
- 11.2.2. Market Revenue and Forecast, by February (2020-2032)
- 11.2.3. Market Revenue and Forecast, by March (2020-2032)
- 11.2.4. UK
- 11.2.4.1. Market Revenue and Forecast, by January (2020-2032)
- 11.2.4.2. Market Revenue and Forecast, by February (2020-2032)
- 11.2.4.3. Market Revenue and Forecast, by March (2020-2032)
- 11.2.5. Germany
- 11.2.5.1. Market Revenue and Forecast, by January (2020-2032)
- 11.2.5.2. Market Revenue and Forecast, by February (2020-2032)
- 11.2.5.3. Market Revenue and Forecast, by March (2020-2032)
- 11.2.6. France
- 11.2.6.1. Market Revenue and Forecast, by January (2020-2032)
- 11.2.6.2. Market Revenue and Forecast, by February (2020-2032)
- 11.2.6.3. Market Revenue and Forecast, by March (2020-2032)
- 11.2.7. Rest of Europe
- 11.2.7.1. Market Revenue and Forecast, by January (2020-2032)
- 11.2.7.2. Market Revenue and Forecast, by February (2020-2032)
- 11.2.7.3. Market Revenue and Forecast, by March (2020-2032)
- 11.3. APAC
- 11.3.1. Market Revenue and Forecast, by January (2020-2032)
- 11.3.2. Market Revenue and Forecast, by February (2020-2032)
- 11.3.3. Market Revenue and Forecast, by March (2020-2032)
- 11.3.4. India
- 11.3.4.1. Market Revenue and Forecast, by January (2020-2032)
- 11.3.4.2. Market Revenue and Forecast, by February (2020-2032)
- 11.3.4.3. Market Revenue and Forecast, by March (2020-2032)
- 11.3.5. China
- 11.3.5.1. Market Revenue and Forecast, by January (2020-2032)
- 11.3.5.2. Market Revenue and Forecast, by February (2020-2032)
- 11.3.5.3. Market Revenue and Forecast, by March (2020-2032)
- 11.3.6. Japan
- 11.3.6.1. Market Revenue and Forecast, by January (2020-2032)
- 11.3.6.2. Market Revenue and Forecast, by February (2020-2032)
- 11.3.6.3. Market Revenue and Forecast, by March (2020-2032)
- 11.3.7. Rest of APAC
- 11.3.7.1. Market Revenue and Forecast, by January (2020-2032)
- 11.3.7.2. Market Revenue and Forecast, by February (2020-2032)
- 11.3.7.3. Market Revenue and Forecast, by March (2020-2032)
- 11.4. MEA
- 11.4.1. Market Revenue and Forecast, by January (2020-2032)
- 11.4.2. Market Revenue and Forecast, by February (2020-2032)
- 11.4.3. Market Revenue and Forecast, by March (2020-2032)
- 11.4.4. GCC
- 11.4.4.1. Market Revenue and Forecast, by January (2020-2032)
- 11.4.4.2. Market Revenue and Forecast, by February (2020-2032)
- 11.4.4.3. Market Revenue and Forecast, by March (2020-2032)
- 11.4.5. North Africa
- 11.4.5.1. Market Revenue and Forecast, by January (2020-2032)
- 11.4.5.2. Market Revenue and Forecast, by February (2020-2032)
- 11.4.5.3. Market Revenue and Forecast, by March (2020-2032)
- 11.4.6. South Africa
- 11.4.6.1. Market Revenue and Forecast, by January (2020-2032)
- 11.4.6.2. Market Revenue and Forecast, by February (2020-2032)
- 11.4.6.3. Market Revenue and Forecast, by March (2020-2032)
- 11.4.7. Rest of MEA
- 11.4.7.1. Market Revenue and Forecast, by January (2020-2032)
- 11.4.7.2. Market Revenue and Forecast, by February (2020-2032)
- 11.4.7.3. Market Revenue and Forecast, by March (2020-2032)
- 11.5. Latin America
- 11.5.1. Market Revenue and Forecast, by January (2020-2032)
- 11.5.2. Market Revenue and Forecast, by February (2020-2032)
- 11.5.3. Market Revenue and Forecast, by March (2020-2032)
- 11.5.4. Brazil
- 11.5.4.1. Market Revenue and Forecast, by January (2020-2032)
- 11.5.4.2. Market Revenue and Forecast, by February (2020-2032)
- 11.5.4.3. Market Revenue and Forecast, by March (2020-2032)
- 11.5.5. Rest of LATAM
- 11.5.5.1. Market Revenue and Forecast, by January (2020-2032)
- 11.5.5.2. Market Revenue and Forecast, by February (2020-2032)
- 11.5.5.3. Market Revenue and Forecast, by March (2020-2032)
- Chapter 12. Company Profiles
- 12.1. Koneksa
- 12.1.1. Company Overview
- 12.1.2. Product Offerings
- 12.1.3. Financial Performance
- 12.1.4. Recent Initiatives
- 12.2. Biogen Inc.
- 12.2.1. Company Overview
- 12.2.2. Product Offerings
- 12.2.3. Financial Performance
- 12.2.4. Recent Initiatives
- 12.3. Amgen Inc.
- 12.3.1. Company Overview
- 12.3.2. Product Offerings
- 12.3.3. Financial Performance
- 12.3.4. Recent Initiatives
- 12.4. Biogen Inc.
- 12.4.1. Company Overview
- 12.4.2. Product Offerings
- 12.4.3. Financial Performance
- 12.4.4. Recent Initiatives
- 12.5. Empatica Inc.
- 12.5.1. Company Overview
- 12.5.2. Product Offerings
- 12.5.3. Financial Performance
- 12.5.4. Recent Initiatives
- 12.6. Vivo Sense
- 12.6.1. Company Overview
- 12.6.2. Product Offerings
- 12.6.3. Financial Performance
- 12.6.4. Recent Initiatives
- 12.7. IXICO plc
- 12.7.1. Company Overview
- 12.7.2. Product Offerings
- 12.7.3. Financial Performance
- 12.7.4. Recent Initiatives
- 12.8. Huma
- 12.8.1. Company Overview
- 12.8.2. Product Offerings
- 12.8.3. Financial Performance
- 12.8.4. Recent Initiatives
- 12.9. Sonde Health, Inc.
- 12.9.1. Company Overview
- 12.9.2. Product Offerings
- 12.9.3. Financial Performance
- 12.9.4. Recent Initiatives
- 12.10. Clario
- 12.10.1. Company Overview
- 12.10.2. Product Offerings
- 12.10.3. Financial Performance
- 12.10.4. Recent Initiatives
- Chapter 13. Research Methodology
- 13.1. Primary Research
- 13.2. Secondary Research
- 13.3. Assumptions
- Chapter 14. Appendix
- 14.1. About Us
- 14.2. Glossary of Terms "
- Chapter 1. Introduction
- 1.1. Research Objective
- 1.2. Scope of the Study
- 1.3. Definition
- Chapter 2. Research Methodology (Premium Insights)
- 2.1. Research Approach
- 2.2. Data Sources
- 2.3. Assumptions & Limitations
- Chapter 3. Executive Summary
- 3.1. Market Snapshot
- Chapter 4. Market Variables and Scope
- 4.1. Introduction
- 4.2. Market Classification and Scope
- 4.3. Industry Value Chain Analysis
- 4.3.1. Raw Material Procurement Analysis
- 4.3.2. Sales and Distribution Channel Analysis
- 4.3.3. Downstream Buyer Analysis
- Chapter 5. COVID 19 Impact on Behavioral Digital Biomarkers Market
- 5.1. COVID-19 Landscape: Behavioral Digital Biomarkers Industry Impact
- 5.2. COVID 19 - Impact Assessment for the Industry
- 5.3. COVID 19 Impact: Global Major Government Policy
- 5.4. Market Trends and Opportunities in the COVID-19 Landscape
- Chapter 6. Market Dynamics Analysis and Trends
- 6.1. Market Dynamics
- 6.1.1. Market Drivers
- 6.1.2. Market Restraints
- 6.1.3. Market Opportunities
- 6.2. Porter’s Five Forces Analysis
- 6.2.1. Bargaining power of suppliers
- 6.2.2. Bargaining power of buyers
- 6.2.3. Threat of substitute
- 6.2.4. Threat of new entrants
- 6.2.5. Degree of competition
- Chapter 7. Competitive Landscape
- 7.1.1. Company Market Share/Positioning Analysis
- 7.1.2. Key Strategies Adopted by Players
- 7.1.3. Vendor Landscape
- 7.1.3.1. List of Suppliers
- 7.1.3.2. List of Buyers
- Chapter 8. Global Behavioral Digital Biomarkers Market, By Type
- 8.1. Behavioral Digital Biomarkers Market, by January, 2023-2032
- 8.1.1 Wearable
- 8.1.1.1. Market Revenue and Forecast (2020-2032)
- 8.1.2. Mobile based Applications
- 8.1.2.1. Market Revenue and Forecast (2020-2032)
- 8.1.3. Sensors
- 8.1.3.1. Market Revenue and Forecast (2020-2032)
- 8.1.4. Others
- 8.1.4.1. Market Revenue and Forecast (2020-2032)
- Chapter 9. Global Behavioral Digital Biomarkers Market, By Clinical Practice
- 9.1. Behavioral Digital Biomarkers Market, by February, 2023-2032
- 9.1.1. Diagnostic Psychiatric Digital Biomarkers
- 9.1.1.1. Market Revenue and Forecast (2020-2032)
- 9.1.2. Monitoring Psychiatric Digital Biomarkers
- 9.1.2.1. Market Revenue and Forecast (2020-2032)
- 9.1.3. Predictive and Prognostic Psychiatric Digital Biomarkers
- 9.1.3.1. Market Revenue and Forecast (2020-2032)
- 9.1.4. Other's (Safety, Pharmacodynamics/ Response, Susceptibility)
- 9.1.4.1. Market Revenue and Forecast (2020-2032)
- Chapter 10. Global Behavioral Digital Biomarkers Market, By End Use
- 10.1. Behavioral Digital Biomarkers Market, by March, 2023-2032
- 10.1.1. Healthcare companies
- 10.1.1.1. Market Revenue and Forecast (2020-2032)
- 10.1.2. Healthcare Providers
- 10.1.2.1. Market Revenue and Forecast (2020-2032)
- 10.1.3. Payers
- 10.1.3.1. Market Revenue and Forecast (2020-2032)
- 10.1.4. Others (Patient, caregivers)
- 10.1.4.1. Market Revenue and Forecast (2020-2032)
- Chapter 11. Global Behavioral Digital Biomarkers Market, Regional Estimates and Trend Forecast
- 11.1. North America
- 11.1.1. Market Revenue and Forecast, by January (2020-2032)
- 11.1.2. Market Revenue and Forecast, by February (2020-2032)
- 11.1.3. Market Revenue and Forecast, by March (2020-2032)
- 11.1.4. U.S.
- 11.1.4.1. Market Revenue and Forecast, by January (2020-2032)
- 11.1.4.2. Market Revenue and Forecast, by February (2020-2032)
- 11.1.4.3. Market Revenue and Forecast, by March (2020-2032)
- 11.1.5. Rest of North America
- 11.1.5.1. Market Revenue and Forecast, by January (2020-2032)
- 11.1.5.2. Market Revenue and Forecast, by February (2020-2032)
- 11.1.5.3. Market Revenue and Forecast, by March (2020-2032)
- 11.2. Europe
- 11.2.1. Market Revenue and Forecast, by January (2020-2032)
- 11.2.2. Market Revenue and Forecast, by February (2020-2032)
- 11.2.3. Market Revenue and Forecast, by March (2020-2032)
- 11.2.4. UK
- 11.2.4.1. Market Revenue and Forecast, by January (2020-2032)
- 11.2.4.2. Market Revenue and Forecast, by February (2020-2032)
- 11.2.4.3. Market Revenue and Forecast, by March (2020-2032)
- 11.2.5. Germany
- 11.2.5.1. Market Revenue and Forecast, by January (2020-2032)
- 11.2.5.2. Market Revenue and Forecast, by February (2020-2032)
- 11.2.5.3. Market Revenue and Forecast, by March (2020-2032)
- 11.2.6. France
- 11.2.6.1. Market Revenue and Forecast, by January (2020-2032)
- 11.2.6.2. Market Revenue and Forecast, by February (2020-2032)
- 11.2.6.3. Market Revenue and Forecast, by March (2020-2032)
- 11.2.7. Rest of Europe
- 11.2.7.1. Market Revenue and Forecast, by January (2020-2032)
- 11.2.7.2. Market Revenue and Forecast, by February (2020-2032)
- 11.2.7.3. Market Revenue and Forecast, by March (2020-2032)
- 11.3. APAC
- 11.3.1. Market Revenue and Forecast, by January (2020-2032)
- 11.3.2. Market Revenue and Forecast, by February (2020-2032)
- 11.3.3. Market Revenue and Forecast, by March (2020-2032)
- 11.3.4. India
- 11.3.4.1. Market Revenue and Forecast, by January (2020-2032)
- 11.3.4.2. Market Revenue and Forecast, by February (2020-2032)
- 11.3.4.3. Market Revenue and Forecast, by March (2020-2032)
- 11.3.5. China
- 11.3.5.1. Market Revenue and Forecast, by January (2020-2032)
- 11.3.5.2. Market Revenue and Forecast, by February (2020-2032)
- 11.3.5.3. Market Revenue and Forecast, by March (2020-2032)
- 11.3.6. Japan
- 11.3.6.1. Market Revenue and Forecast, by January (2020-2032)
- 11.3.6.2. Market Revenue and Forecast, by February (2020-2032)
- 11.3.6.3. Market Revenue and Forecast, by March (2020-2032)
- 11.3.7. Rest of APAC
- 11.3.7.1. Market Revenue and Forecast, by January (2020-2032)
- 11.3.7.2. Market Revenue and Forecast, by February (2020-2032)
- 11.3.7.3. Market Revenue and Forecast, by March (2020-2032)
- 11.4. MEA
- 11.4.1. Market Revenue and Forecast, by January (2020-2032)
- 11.4.2. Market Revenue and Forecast, by February (2020-2032)
- 11.4.3. Market Revenue and Forecast, by March (2020-2032)
- 11.4.4. GCC
- 11.4.4.1. Market Revenue and Forecast, by January (2020-2032)
- 11.4.4.2. Market Revenue and Forecast, by February (2020-2032)
- 11.4.4.3. Market Revenue and Forecast, by March (2020-2032)
- 11.4.5. North Africa
- 11.4.5.1. Market Revenue and Forecast, by January (2020-2032)
- 11.4.5.2. Market Revenue and Forecast, by February (2020-2032)
- 11.4.5.3. Market Revenue and Forecast, by March (2020-2032)
- 11.4.6. South Africa
- 11.4.6.1. Market Revenue and Forecast, by January (2020-2032)
- 11.4.6.2. Market Revenue and Forecast, by February (2020-2032)
- 11.4.6.3. Market Revenue and Forecast, by March (2020-2032)
- 11.4.7. Rest of MEA
- 11.4.7.1. Market Revenue and Forecast, by January (2020-2032)
- 11.4.7.2. Market Revenue and Forecast, by February (2020-2032)
- 11.4.7.3. Market Revenue and Forecast, by March (2020-2032)
- 11.5. Latin America
- 11.5.1. Market Revenue and Forecast, by January (2020-2032)
- 11.5.2. Market Revenue and Forecast, by February (2020-2032)
- 11.5.3. Market Revenue and Forecast, by March (2020-2032)
- 11.5.4. Brazil
- 11.5.4.1. Market Revenue and Forecast, by January (2020-2032)
- 11.5.4.2. Market Revenue and Forecast, by February (2020-2032)
- 11.5.4.3. Market Revenue and Forecast, by March (2020-2032)
- 11.5.5. Rest of LATAM
- 11.5.5.1. Market Revenue and Forecast, by January (2020-2032)
- 11.5.5.2. Market Revenue and Forecast, by February (2020-2032)
- 11.5.5.3. Market Revenue and Forecast, by March (2020-2032)
- Chapter 12. Company Profiles
- 12.1. Koneksa
- 12.1.1. Company Overview
- 12.1.2. Product Offerings
- 12.1.3. Financial Performance
- 12.1.4. Recent Initiatives
- 12.2. Biogen Inc.
- 12.2.1. Company Overview
- 12.2.2. Product Offerings
- 12.2.3. Financial Performance
- 12.2.4. Recent Initiatives
- 12.3. Amgen Inc.
- 12.3.1. Company Overview
- 12.3.2. Product Offerings
- 12.3.3. Financial Performance
- 12.3.4. Recent Initiatives
- 12.4. Biogen Inc.
- 12.4.1. Company Overview
- 12.4.2. Product Offerings
- 12.4.3. Financial Performance
- 12.4.4. Recent Initiatives
- 12.5. Empatica Inc.
- 12.5.1. Company Overview
- 12.5.2. Product Offerings
- 12.5.3. Financial Performance
- 12.5.4. Recent Initiatives
- 12.6. Vivo Sense
- 12.6.1. Company Overview
- 12.6.2. Product Offerings
- 12.6.3. Financial Performance
- 12.6.4. Recent Initiatives
- 12.7. IXICO plc
- 12.7.1. Company Overview
- 12.7.2. Product Offerings
- 12.7.3. Financial Performance
- 12.7.4. Recent Initiatives
- 12.8. Huma
- 12.8.1. Company Overview
- 12.8.2. Product Offerings
- 12.8.3. Financial Performance
- 12.8.4. Recent Initiatives
- 12.9. Sonde Health, Inc.
- 12.9.1. Company Overview
- 12.9.2. Product Offerings
- 12.9.3. Financial Performance
- 12.9.4. Recent Initiatives
- 12.10. Clario
- 12.10.1. Company Overview
- 12.10.2. Product Offerings
- 12.10.3. Financial Performance
- 12.10.4. Recent Initiatives
- Chapter 13. Research Methodology
- 13.1. Primary Research
- 13.2. Secondary Research
- 13.3. Assumptions
- Chapter 14. Appendix
- 14.1. About Us
- 14.2. Glossary of Terms
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook